{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:51:24Z","timestamp":1771879884459,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104156","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T03:16:21Z","timestamp":1662347781000},"page":"104156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Angela","family":"Albanese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-2977","authenticated-orcid":false,"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2022.104156_bib0001","doi-asserted-by":"crossref","first-page":"e1141","DOI":"10.1212\/NXI.0000000000001141","article-title":"Risk of getting COVID-19 in people with multiple sclerosis: a case-control study","volume":"9","author":"Iaffaldano","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104156_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.704110","article-title":"COVID-19 vaccination in fragile patients: current evidence and an harmonized transdisease trial","volume":"12","author":"Agrati","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2022.104156_bib0003","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.3390\/jcm9124066","article-title":"Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: the hidden part of the iceberg","volume":"9","author":"Capasso","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2022.104156_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2022.104156_bib0005","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1177\/1352458520971817","article-title":"COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments","volume":"27","author":"Laroni","year":"2021","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2022.104156_bib0006","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104156_bib0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a north american registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"issue":"19","key":"10.1016\/j.msard.2022.104156_bib0008","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.104156_bib0009","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104156_bib0010","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.25770","article-title":"SARS-COV -2 and multiple sclerosis: not all immune depleting DMTS are equal or bad","volume":"87","author":"Amor","year":"2020","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.104156_bib0011","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-020-00756-y","article-title":"Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination","volume":"34","author":"Zheng","year":"2020","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.msard.2022.104156_bib0012","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10072-020-04519-x","article-title":"Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study","volume":"41","author":"Dalla Costa","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104156_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102453","article-title":"Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients","volume":"46","author":"Mantero","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104156_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","volume":"57","author":"Schiavetti","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"15","key":"10.1016\/j.msard.2022.104156_bib0015","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiologya proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2022.104156_bib0016","first-page":"59","article-title":"Seroprevalence of SARS-CoV-2 in multiple sclerosis patients under immunomodulatory treatment in lleida (study em COVID-19)","author":"Hervas-Garcia","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.104156_bib0017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5603\/PJNNS.a2021.0031","article-title":"Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience","volume":"55","author":"Czarnowska","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"issue":"5","key":"10.1016\/j.msard.2022.104156_bib0018","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1212\/NXI.0000000000001024","article-title":"SARS-CoV-2 infection in multiple sclerosis: results of the spanish neurology society registry","volume":"8","author":"Arrambide","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2022.104156_bib0019","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/13524585211026272","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry","volume":"28","author":"Spelman","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104156_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103150","article-title":"Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies","volume":"54","author":"Drulovic","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104156_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103173","article-title":"Coronavirus disease 2019 in Latin American patients with multiple sclerosis","volume":"55","author":"Fragoso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2022.104156_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255316","article-title":"AUT-MuSC investigators. COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: insights from a nation-wide Austrian registry","volume":"16","author":"Bsteh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.104156_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103217","article-title":"COVID-19 severity and outcome in multiple sclerosis: results of a national, registry-based, matched cohort study","volume":"55","author":"P\u00e9rez","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"18","key":"10.1016\/j.msard.2022.104156_bib0024","first-page":"1358","article-title":"Clinical outcomes in patients with COVID-19 during two phase IV studies of cladribine tablets for treatment of multiple sclerosis: an update (P11-4.005)","volume":"98","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104156_bib0025","doi-asserted-by":"crossref","first-page":"e1001","DOI":"10.1212\/NXI.0000000000001001","article-title":"COVID-19 among patients with multiple sclerosis: a systematic review","volume":"8","author":"Barzegar","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104156_bib0026","unstructured":"Coronavirus Disease 2019 (COVID-19): Epidemiology update. Updated: September 20, 2020. Accessed September 21, 2020. health-infobase.canada.ca\/COVID-19\/epidemiological-summary-COVID-19-cases.htm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:09:34Z","timestamp":1761901774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"alternative-id":["S2211034822006630"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104156","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104156"}}